# Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

> **NCT04556539** · PHASE2 · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **DRUG:** SC10914

## Key facts

- **NCT ID:** NCT04556539
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04556539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04556539, "Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT04556539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*